Kronos Bio LLC

Kronos Bio LLC Equity

Delisted

The The Equity of Kronos Bio LLC (KRON) as of Nov 2, 2026 is 87.58 M USD. In the previous year, The Equity was 159.08 M USD — a change of -44.95% (lower).

Equity

87.58 MUSD

YoY

-44.95%

Last updated:

In 2024, Kronos Bio LLC's equity was 87.58 M USD, a -44.95% increase from the 159.08 M USD equity in the previous year.

The Kronos Bio LLC Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-7.30 M USD
Jan 1, 2019
-23.20 M USD
Jan 1, 2020
465.52 M USD
Jan 1, 2021
345.10 M USD
Jan 1, 2022
244.50 M USD
Jan 1, 2023
159.08 M USD
Jan 1, 2024
87.58 M USD
The Kronos Bio LLC Equity history
YEAREquityYoY
87.58 MUSD-44.95%
159.08 MUSD-34.94%
244.50 MUSD-29.15%
345.10 MUSD-25.87%
465.52 MUSD-2,106.29%
-23.20 MUSD+218.02%
-7.30 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kronos Bio LLC Stock analysis

What does Kronos Bio LLC do? Kronos Bio Inc is a biotech company founded in 2017 by an experienced team, specialized in developing new therapeutics for cancer treatment. The company is based in Cambridge, Massachusetts and collaborates closely with leading scientific institutions. Kronos Bio Inc's business model focuses on identifying and researching new targets to develop drugs for the treatment of cancer and other diseases. The company utilizes artificial intelligence and machine learning to identify molecular mechanisms, enabling better prediction of the effectiveness of new drugs. Kronos Bio Inc is divided into different divisions, each focusing on specific therapeutic approaches. The "Transcription Regulation" division explores the control of gene expression in tumor cells and seeks potential points of intervention. The "Epigenetics" division, on the other hand, investigates how cells modify their DNA and the role this plays in the development of cancer. Another division focuses on blocking specific enzyme activities that are considered essential factors for the growth of tumor cells. Currently, Kronos Bio Inc does not offer concrete products as it is still in the development phase. However, the company has already established a number of collaborations with other companies and scientific institutions to research and further develop new drug candidates. One of the most significant partnerships is with the pharmaceutical company Gilead Sciences, which has the option to license selected drug candidates from Kronos Bio Inc as part of the collaboration. Overall, Kronos Bio has quickly made a name for itself in the biotech industry with its innovative approach and ambitious plans to develop new drugs against cancer. The company has raised several million dollars in capital and has prominent investors such as Omega Funds and Vida Ventures on board. The goal of Kronos Bio is to develop new therapies that allow for improved survival rates and a higher quality of life for cancer patients. Kronos Bio LLC is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Kronos Bio LLC's Equity

Kronos Bio LLC's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Kronos Bio LLC's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Kronos Bio LLC's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Kronos Bio LLC's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Kronos Bio LLC’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Kronos Bio LLC stock

The Equity of Kronos Bio LLC is 87.58 M USD in 2024.

The Equity of Kronos Bio LLC changed from 159.08 M USD to 87.58 M USD, representing a -44.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Kronos Bio LLC since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Kronos Bio LLC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Kronos Bio LLC

All Key Metrics — Kronos Bio LLC